

## Catalog # 10-4564 NLG919

CAS# 1402836-58-1 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol Lot # FBS2001

NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM;  $EC_{50}$  = 75nM). It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma. In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN- $\gamma$  and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.

- 1) Mautino et al. (2013), NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy; Cancer Res. **73** issue 8 supplement 491
- 2) Li et al. (2014), The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma; J. Immunother. Cancer **2** 21
- 3) Meng et al. (2017), Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model; Int. J. Immunopathol. Pharmacol. **30** 215

## PHYSICAL DATA

Molecular Weight: 282.39

Molecular Formula: C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O

Purity: >98% by HPLC

NMR: (Conforms)

Solubility: DMSO (15 mg/ml)

Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462 www.focusbiomolecules.com